Summary by Moomoo AI
SciSparc Ltd., a foreign private issuer, reported on March 12, 2024, that its collaborative venture MitoCareX Bio Ltd. has made significant progress in the development of cancer therapeutics. MitoCareX, working with Dr. Alon Silberman, has virtually screened millions of small molecules using a computational drug discovery platform, identifying several with potential anti-cancer properties. These findings were validated through in-vitro screening systems targeting the mitochondrial SLC25 protein family. Furthermore, MitoCareX is advancing towards the creation of a predictive AI model to enhance the efficiency of navigating chemical spaces and discovering novel anti-cancer scaffolds. The report includes forward-looking statements and is incorporated by reference into the company's registration statements filed with the SEC. SciSparc's CEO and CFO, Oz Adler, signed the report on March 13, 2024.